Responses
Immune cell therapies and immune cell engineering
Original research
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML
Compose a Response to This Article
Other responses
No responses have been published for this article.
